153 related articles for article (PubMed ID: 35368946)
1. Clinical Efficacy of Yiqi Yangyin Decoction Combined with Docetaxel on Advanced Ovarian Cancer and the Effect on the Levels of Serum Markers VEGF, HE4, and CA125.
Wang N; Xiao F; Shao H; Shi S; Zhou Y
J Healthc Eng; 2022; 2022():8401202. PubMed ID: 35368946
[TBL] [Abstract][Full Text] [Related]
2. Comparisons of efficacy and safety between docetaxel + cisplatin and paclitaxel + cisplatin and their effects on serum HE4, CA125 and ROMA indicators in patients with ovarian carcinoma.
Han L; Kuang L
J BUON; 2019; 24(4):1544-1548. PubMed ID: 31646806
[TBL] [Abstract][Full Text] [Related]
3. Retracted: Clinical Efficacy of Yiqi Yangyin Decoction Combined with Docetaxel on Advanced Ovarian Cancer and the Effect on the Levels of Serum Markers VEGF, HE4, and CA125.
Healthcare Engineering JO
J Healthc Eng; 2023; 2023():9834612. PubMed ID: 37476810
[TBL] [Abstract][Full Text] [Related]
4. The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer.
Sun J; Cui XW; Li YS; Wang SY; Yin Q; Wang XN; Gu L
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7276-7283. PubMed ID: 32706065
[TBL] [Abstract][Full Text] [Related]
5. Clinical Effects of Chinese Herbal Decoction Combined with Basic Chemoradiotherapy and Nursing Intervention in the Treatment of Cervical Cancer and the Effect on Serum CEA, CA125, and TNF-
Gao L; Lv J; Hou L; Yuan Y; Wan Q
Evid Based Complement Alternat Med; 2021; 2021():1446864. PubMed ID: 34603461
[TBL] [Abstract][Full Text] [Related]
6. Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study.
Feng LY; Liao SB; Li L
J Ovarian Res; 2020 Feb; 13(1):17. PubMed ID: 32050995
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125.
Schummer M; Drescher C; Forrest R; Gough S; Thorpe J; Hellström I; Hellström KE; Urban N
Gynecol Oncol; 2012 Apr; 125(1):65-9. PubMed ID: 22155417
[TBL] [Abstract][Full Text] [Related]
8. Early clearance of serum HE4 and CA125 in predicting platinum sensitivity and prognosis in epithelial ovarian cancer.
Rong Y; Li L
J Ovarian Res; 2021 Jan; 14(1):2. PubMed ID: 33397458
[TBL] [Abstract][Full Text] [Related]
9. Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis.
Zhang L; Chen Y; Wang K
Curr Probl Cancer; 2019 Apr; 43(2):135-144. PubMed ID: 30017407
[TBL] [Abstract][Full Text] [Related]
10. The clinical value of the combined detection of sEGFR, CA125 and HE4 for epithelial ovarian cancer diagnosis.
Li Y; Wang ZC; Luo L; Mu CY; Xu J; Feng Q; Li SB; Gu B; Ma P; Lan T
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):604-610. PubMed ID: 32016961
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of bevacizumab combined with nedaplatin in the treatment of ovarian cancer and its effects on tumor markers and immunity of patients.
Zhang H; Chen C; Wang S; Li X; Fan T
J BUON; 2020; 25(1):80-86. PubMed ID: 32277617
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK
Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.
Ahmed AA; Abdou AM
Curr Probl Cancer; 2019 Oct; 43(5):450-460. PubMed ID: 30670303
[TBL] [Abstract][Full Text] [Related]
14. Retrospective efficacy analysis of olaparib combined with bevacizumab in the treatment of advanced colorectal cancer.
Jiang YL; Fu XY; Yin ZH
World J Gastrointest Surg; 2023 May; 15(5):906-916. PubMed ID: 37342840
[TBL] [Abstract][Full Text] [Related]
15. The Efficacy of Psychological Care and Chinese Herbal Decoction in Postoperative Chemotherapy Patients with Endometrial Cancer.
Liu J; Wang J; Guo Y; Zhang H
J Healthc Eng; 2022; 2022():5700637. PubMed ID: 35222888
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of serum cancer antigen 125, human epididymis protein 4, ROMA, and CPH-I for diagnosis of ovarian cancer in Chinese patients with ovarian mass].
Shipeng G; Yongning C; Yadi Z; Chanyuan LI; Qifan J
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Dec; 39(12):1393-1401. PubMed ID: 31907150
[TBL] [Abstract][Full Text] [Related]
17. Effect of sitagliptin combined with Yiqi yangyin huoxue decoction on clinical efficacy and hemorheology in early diabetic nephropathy.
Ling J; Yang YH
World J Diabetes; 2023 Sep; 14(9):1412-1421. PubMed ID: 37771333
[TBL] [Abstract][Full Text] [Related]
18. Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer.
Vallius T; Hynninen J; Auranen A; Carpén O; Matomäki J; Oksa S; Virtanen J; Grénman S
Tumour Biol; 2014 Dec; 35(12):12389-95. PubMed ID: 25190018
[TBL] [Abstract][Full Text] [Related]
19. Measurement of HE4 six months after first-line treatment as optimal time in identifying patients at high risk of progression advanced ovarian cancer.
Kotowicz BU; Fuksiewicz M; Bidzinski M; Berezowska A; Sobiczewski P; Kowalska MM
Ginekol Pol; 2022; 93(11):910-915. PubMed ID: 36621970
[TBL] [Abstract][Full Text] [Related]
20. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].
Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J
Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]